Akèy › Maladi Crohn
Etid klinik pou Maladi Crohn ap rekrite nan Etazini
93 etid pou Maladi Crohn ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY35 etid
- St. Louis, MO19 etid
- Boston, MA19 etid
- Miami, FL19 etid
- Cleveland, OH19 etid
- Atlanta, GA17 etid
- Orlando, FL17 etid
- Houston, TX17 etid
- Tyler, TX16 etid
- San Antonio, TX15 etid
- Los Angeles, CA15 etid
- San Diego, CA15 etid
- Colorado Springs, CO13 etid
- Philadelphia, PA13 etid
- Providence, RI12 etid
- Durham, NC12 etid
- Pittsburgh, PA11 etid
- Seattle, WA11 etid
- Cincinnati, OH11 etid
- Tacoma, WA11 etid
- Dallas, TX10 etid
- Washington, DC10 etid
- Tampa, FL10 etid
- Baltimore, MD10 etid
- Lubbock, TX10 etid
- Indianapolis, IN10 etid
- Chicago, IL9 etid
- Lewisville, TX9 etid
- Ann Arbor, MI9 etid
- Evanston, IL9 etid
- Louisville, KY9 etid
- New Haven, CT8 etid
- Parma, OH8 etid
- Rochester, MN8 etid
- Charlotte, NC8 etid
- Columbus, OH8 etid
- Independence, MO8 etid
- Las Vegas, NV7 etid
- Milwaukee, WI7 etid
- Round Rock, TX7 etid
Pa eta
- Alabama9 etid
- Arizona17 etid
- Arkansas3 etid
- Colorado18 etid
- Connecticut14 etid
- Distrik Columbia4 etid
- Florid27 etid
- Georgia22 etid
- Idaho4 etid
- Illinois18 etid
- Indiana12 etid
- Iowa8 etid
- Kalifòni37 etid
- Kansas11 etid
- Kentucky12 etid
- Lwizyàn11 etid
- Maryland15 etid
- Massachusetts27 etid
- Michigan19 etid
- Minnesota11 etid
- Mississippi3 etid
- Missouri21 etid
- Nevada8 etid
- New Hampshire3 etid
- New Jersey9 etid
- New York36 etid
- North Carolina20 etid
- Ohio30 etid
- Oklahoma8 etid
- Oregon4 etid
- Pennsylvania23 etid
- Rhode Island12 etid
- South Carolina11 etid
- South Dakota4 etid
- Tennessee10 etid
- Texas35 etid
- Utah8 etid
- Virginia15 etid
- Washington22 etid
- Wisconsin7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
Ap rekriteVolontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07852273Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07697456Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Oct 1, 2026 · NCT07619547A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 29, 2026 · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Ap rekriteFaz 3
Laj 3 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06663332Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06233461Non-nutritive Sweeteners in Inflammatory Bowel Disease
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07769437A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT05923073Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
Ap rekrite
Laj 16 a 75 · Tout sèks · Mizajou Sep 24, 2026 · NCT07671872A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 23, 2026 · NCT05995353Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483099A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483073A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ap rekriteFaz 3
Laj 2 a 19 · Tout sèks · Mizajou Sep 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Sep 9, 2026 · NCT06651281Standardized Microbiota Transplant Therapy in Crohn's Disease
Ap rekriteFaz 2
Laj 18 a 89 · Tout sèks · Mizajou Sep 8, 2026 · NCT06631586Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.